Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
暂无分享，去创建一个
I. Vergote | U. Matulonis | S. Lau | E. Kalbacher | D. Berton‐Rigaud | M. Mirza | A. du Bois | B. Benigno | J. Herrstedt | S. Mahner | D. Lorusso | A. Dørum | B. Rimel | J. Buscema | J. Ledermann | B. Rimel | A. Bois | A. C. Herráez | P. Bessette | I. B. Barcelo | T. Levy | P. Wang | F. D. de Jong | D. Gupta | U. Matulonis | I. Barcelo | D. Berton-Rigaud | P. Wang | Benedict B. Benigno | Sven Mahner | IM Bover Barcelo | D. Berton-Rigaud | J. Ledermann | Jørn Herrstedt | Susie K Lau | Tally Levy | F. A. D. Jong